Table 3.

Adjusted association between patients' characteristics and PSA results

PSA conducted (N = 9,267)PSA≥4 ng/mL (N = 2,486)
OR (95% CI)P valueOR (95% CI)P value
Age1.00 (0.99–1.01)0.4661.08 (1.04–1.12)<0.001
Race ethnicity<0.001a<0.001a
 African-American1.00 (—)1.00 (—)
 Non-Hispanic white0.68 (0.55–0.83)<0.0010.38 (0.21–0.70)0.002
 Hispanic0.95 (0.79–1.15)0.6040.34 (0.20–0.57)<0.001
 Other0.79 (0.57–1.09)0.1480.35 (0.12–1.08)0.068
Benign prostatic hyperplasia1.99 (1.63–2.36)<0.0011.24 (0.73–2.11)0.432
No. of non–prostate-related clinical conditions0.014a0.381a
 01.00 (—)1.00 (—)
 11.14 (0.99–1.31)0.0701.10 (0.66–1.84)0.711
 21.01 (0.88–1.16)0.9260.90 (0.53–1.51)0.680
 ≥30.90 (0.77–1.06)0.2140.67 (0.35–1.28)0.228
Insurance type<0.001a0.497a
 CareLink A1.33 (1.12–1.58)0.0010.74 (0.36–1.55)0.429
 CareLink Other1.46 (1.28–1.66)<0.0011.25 (0.79–1.99)0.348
 Medicaid0.96 (0.79–1.17)0.7030.64 (0.26–1.56)0.325
 Medicare1.00 (—)1.00 (—)
 Private/state agency1.17 (1.00–1.38)0.0551.00 (0.54–1.84)0.997
 Other0.65 (0.46–0.92)0.0160.87 (0.19–3.92)0.859
Length of observation1.58 (1.47–1.70)<0.0011.10 (0.82–1.48)0.512
  • aBased on Wald χ2 test for testing the overall effect of a categorical variable.